Next Article in Journal
Expression Characteristics and Prognostic Value of KLRG2 in Endometrial Cancer: A Comprehensive Analysis Based on Multi-Omics Data
Previous Article in Journal
Applications of CRISPR-Cas-Based Genome Editing Approaches Against Human Cytomegalovirus Infection
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Retraction

RETRACTED: Paucarmayta et al. Progesterone-Calcitriol Combination Enhanced Cytotoxicity of Cisplatin in Ovarian and Endometrial Cancer Cells In Vitro. Biomedicines 2020, 8, 73

1
Department of Obstetrics & Gynecology, Uniformed Services University, 4301 Jones Bridge Road, Bethesda, MD 20814, USA
2
Gynecologic Cancer Center of Excellence, Department of Obstetrics and Gynecology, Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center, 8901 Wisconsin Avenue, Bethesda, MD 20889, USA
3
John P. Murtha Cancer Center, Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center, 8901 Wisconsin Avenue, Bethesda, MD 20889, USA
4
Gynecologic Cancer Center of Excellence, Women’s Health Integrated Research Center at Inova Health System, 3289 Woodburn Road, Suite 370, Annandale, VA 22003, USA
5
Inova Fairfax Hospital, Department of Obstetrics & Gynecology, 3300 Gallows Road, Falls Church, VA 22042, USA
6
Department of Molecular and Cell Biology, Uniformed Services University, 4301 Jones Bridge Road, Bethesda, MD 20814, USA
*
Author to whom correspondence should be addressed.
Biomedicines 2025, 13(7), 1591; https://doi.org/10.3390/biomedicines13071591
Submission received: 12 March 2025 / Accepted: 18 June 2025 / Published: 30 June 2025
(This article belongs to the Section Cancer Biology and Oncology)
The journal retracts the article, “Progesterone-Calcitriol Combination Enhanced Cytotoxicity of Cisplatin in Ovarian and Endometrial Cancer Cells In Vitro” [1], cited above.
Following publication, concerns were brought to the attention of the publisher regarding image duplication and the overall reliability of several figures presented in this article.
Adhering to our standard procedure, an investigation was conducted by the Editorial Office and Editorial Board, with input from the Uniformed Services University of the Health Sciences, USA. The investigation confirmed duplications between Figure 4A, ERK1/2 panel [1] and Figure 5D, ERK panel published in [2] and between Figure 5C, ABCG1 panel [1] and Figure 3C, p-STAT 3 panel [3], presenting different experimental conditions and originating from a different authorship group. As a result, the Editorial Board has lost confidence in the integrity of the findings and has decided to retract this article [1] as per MDPI’s retraction policy (https://www.mdpi.com/ethics#_bookmark30, accessed on 12 March 2025).
This retraction was approved by the Editor-in-Chief of the journal Biomedicines.
A.P., H.T., L.M., Y.C., G.L.M., and K.M.D. agreed to the retraction. The remaining author did not provide a comment on this decision.

References

  1. Paucarmayta, A.; Taitz, H.; McGlorthan, L.; Casablanca, Y.; Maxwell, G.L.; Darcy, K.M.; Syed, V. RETRACTED: Progesterone-Calcitriol Combination Enhanced Cytotoxicity of Cisplatin in Ovarian and Endometrial Cancer Cells In Vitro. Biomedicines 2020, 8, 73. [Google Scholar] [CrossRef] [PubMed]
  2. Nokin, M.-J.; Bellier, J.; Durieux, F.; Peulen, O.; Rademaker, G.; Gabriel, M.; Monseur, C.; Charloteaux, B.; Verbeke, L.; van Laere, S.; et al. Methylglyoxal, a glycolysis metabolite, triggers metastasis through MEK/ERK/SMAD1 pathway activation in breast cancer. Breast Cancer Res. 2019, 21, 1–19. [Google Scholar] [CrossRef] [PubMed]
  3. Lin, S.-Y.; Chang, H.-H.; Lai, Y.-H.; Lin, C.-H.; Chen, M.-H.; Chang, G.-C.; Tsai, M.-F.; Chen, J.J.W. Digoxin Suppresses Tumor Malignancy through Inhibiting Multiple Src-Related Signaling Pathways in Non-Small Cell Lung Cancer. PLoS ONE 2015, 10, e0123305. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Paucarmayta, A.; Taitz, H.; McGlorthan, L.; Casablanca, Y.; Maxwell, G.L.; Darcy, K.M.; Syed, V. RETRACTED: Paucarmayta et al. Progesterone-Calcitriol Combination Enhanced Cytotoxicity of Cisplatin in Ovarian and Endometrial Cancer Cells In Vitro. Biomedicines 2020, 8, 73. Biomedicines 2025, 13, 1591. https://doi.org/10.3390/biomedicines13071591

AMA Style

Paucarmayta A, Taitz H, McGlorthan L, Casablanca Y, Maxwell GL, Darcy KM, Syed V. RETRACTED: Paucarmayta et al. Progesterone-Calcitriol Combination Enhanced Cytotoxicity of Cisplatin in Ovarian and Endometrial Cancer Cells In Vitro. Biomedicines 2020, 8, 73. Biomedicines. 2025; 13(7):1591. https://doi.org/10.3390/biomedicines13071591

Chicago/Turabian Style

Paucarmayta, Ana, Hannah Taitz, Latoya McGlorthan, Yovanni Casablanca, G. Larry Maxwell, Kathleen M. Darcy, and Viqar Syed. 2025. "RETRACTED: Paucarmayta et al. Progesterone-Calcitriol Combination Enhanced Cytotoxicity of Cisplatin in Ovarian and Endometrial Cancer Cells In Vitro. Biomedicines 2020, 8, 73" Biomedicines 13, no. 7: 1591. https://doi.org/10.3390/biomedicines13071591

APA Style

Paucarmayta, A., Taitz, H., McGlorthan, L., Casablanca, Y., Maxwell, G. L., Darcy, K. M., & Syed, V. (2025). RETRACTED: Paucarmayta et al. Progesterone-Calcitriol Combination Enhanced Cytotoxicity of Cisplatin in Ovarian and Endometrial Cancer Cells In Vitro. Biomedicines 2020, 8, 73. Biomedicines, 13(7), 1591. https://doi.org/10.3390/biomedicines13071591

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop